AFWG shall not bear any responsibility for any content on such sites. Any link to a third-party site does not constitute an endorsement of the third party, their site or services. AFWG also makes no warranties as to the content of such sites.
Would you like to continue?
Harsimran Kaur and Arunaloke Chakrabarti
Postgraduate Institute of Medical Education and Research
Chandigarh, India
Mycetoma is a chronic granulomatous subcutaneous disease caused by bacteria (actinomycetoma) or fungi (eumycetoma). The disease progresses over months to years from a localized painless swelling to plaques, nodules and multiple discharging sinuses extruding grains (Figure), subsequently spreading to underlying muscle, tendons and bone, causing permanent deformities. Because of its typical tropical and subtropical distribution extending between 15º south and 30º north latitude (a zone called the ‘mycetoma belt’), comprising developing countries mainly, and its neglected status, the World Health Organization (WHO) declared mycetoma as a neglected tropical disease.1-3 However, its true distribution extends beyond this belt.
A rough estimate of mycetoma epidemiology by van de Sande indicated the most cases in Mexico, Sudan, Senegal and India, with few reports from Uganda, Romania, Nigeria, Bulgaria and Thailand.3 The frequency varies with different geographic locations.3-15 Actinomycetomas are predominant in dry areas, especially in North Africa, Central and South America and a few Asian countries, while eumycetoma prevails in tropical and subtropical regions of Asia (Mid-East, India) and Africa (Sub-Saharan Africa), where rainfall is abundant.16 This is in contrast to the distribution in India, where eumycetoma is common in the dry western regions of Rajasthan, while eastern Rajasthan and southern India report a high rate of actinomycetomas despite sufficient rainfall in these regions.3,17 Although the meta-analysis by van de Sande gave an overview of epidemiology, the true magnitude of the disease is still ambiguous, as majority of the cases from the endemic regions are not reported in literature.
Figure. Mycetoma of foot with multiple discharging sinuses
Photo courtesy of Professor BM Hemashettar, India
The data on mycetoma in Asia are scarce and mostly based on case reports from single centers. The heaviest burden of the disease is limited to Southeast Asia, the Middle East and, less commonly, in the Far East.2 It was in Madurai (formerly Madura), India, where Gill, Colebrook and Godfrey first described this disease as ‘Madura foot’, which was later renamed ‘mycetoma’ by Carter.2 Current available data show pockets of distribution of mycetoma in Rajasthan, Tamil Nadu and West Bengal provinces in India, with few scattered case reports from Punjab, Madhya Pradesh and Andhra Pradesh.3 Overall, eumycetoma is more common in Rajasthan (62.5%), while actinomycetoma is more prevalent (54.3%-83.3%) in the rest of the country.3 Causative agents also vary within India. Madurella mycetomatis is the most common agent, followed by M. grisea and Aspergillus nidulans in North West India, while species causing eumycetoma in South India include M. mycetomatis, Neoscytalidium dimidiatum and A. flavus.17 The red grain mycetoma, Actinomadura pelletieri, is rare in India.17
Studies from Iran and Thailand have shown predominance of actinomycetoma (84.5% and 64.7%, respectively), while studies from Yemen demonstrate high prevalence of eumycetoma (71%).15,18-21 The most common agents of actinomycetoma in Iran are Actinomadura madurae (23.5%), Nocardia asteroides (20.6%), Nocardia caviae (13.2%); Pseudoallescheria boydii (10.3%) is the common cause of eumycetoma.18,19,22 The prevalence of mycetoma in China is quite low, with around 19 cases reported between 1960 and 2010 (10 eumycetoma; 9 actinomycetoma). The etiologic agents reported from Chinese population include Nocardia brasiliensis, Nocardia asteroides, Nocardia otitidiscaviarum, Actinomadura madurae, Acremonium falciforme, Scopulariopsis maduromycosis, Pseudallescheria boydii, Madurella mycetomatis, Madurella pseudomycetomatis, Trichophyton verrucosum and Aspergillus spp.23 Sporadic cases of mycetoma are reported from Singapore (Monosporium apiospermum), Malaysia (Phialophora jeanselmei, Madurella mycetomi, Streptomyces somaliensis), Philippines (Madurella grisea), Indonesia (Madurella tropicana), Laos (Actinomadura madurae), Cambodia (Pyrenochaeta romeroi, Madura mycetes), Thailand (Nocardia asteroids, N. caviae, N. brasiliensis, N. rosatii, Madurella mycetomii, Pseudallescheria boydii, Exophiala jeanselmei, Actinomadura madurae, Cladosporium carrionii), and Vietnam (Nocardia otitidiscaviarum).24
The disease generally affects young men from rural areas working barefoot outdoors (for activities such as farming, for instance). However, in Thailand, there is an equal prevalence of mycetoma in men and women.3 The disease usually occurs by inoculation of the etiologic agent at the body site, most commonly foot (80%), followed by leg, trunk (less common in Asia) and arm.3
An early diagnosis of the disease is necessary to prevent disfigurement, and identification of the etiologic agent is required for guiding management. The diagnosis is quite challenging in developing countries, where there is a lack of facilities, forcing the clinicians to assess the disease clinically and manage the patient without accurate identification of the pathogen or determining the extent of disease by imaging. Ultrasound and fine needle aspiration are the minimum requirements to accurately diagnose the disease. Other imaging modalities include X-ray, computed tomography (CT) and magnetic resonance imaging (MRI), which are lacking in peripheral and remote areas of developing nations. Culture methods, the gold standard for identification, have limitations of long turnaround time, difficulty isolating the true causative agent from contaminating bacteria and saprophytic fungi, and the need for experienced personnel. Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) is a rapid technique of identification but is available only in a few reference centers. Other modalities like histology, cytology, skin test and serology lack specificity for identification. Molecular methods may improve diagnostic capabilities, but are too expensive to be available at all centers in developing countries.
The treatment is chosen only after distinguishing if the disease is an actinomycetoma or a eumycetoma. Surgical debridement and medical management by antibiotics or antifungal agents are the cornerstones of mycetoma treatment.2 However, the rate of recurrence is quite high, probably due to poor compliance or poor response to the drugs. The prognosis of actinomycetoma is better than eumycetoma.
There are many gaps in knowledge regarding the epidemiology and management of mycetoma. The exact magnitude of disease burden in Asia is still a mystery that needs to be solved to fill in these gaps. Clearly, awareness must be raised among health professionals for early diagnosis and treatment of mycetoma.